ArticleFrontiers in oncology2026
Clinical implications of 10-formyltetrahydrofolate dehydrogenase expression in hormone receptor-positive breast cancer.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: ALDH1L1, a key enzyme in folate metabolism, has been implicated in various cancers, but the clinical significance of its expression in breast cancer remains unclear. Methods: We analyzed three cohorts from Seoul National University Hospital: (i) 41 non-matched patient samples (23 samples from normal mammary tissues and 18 samples from invasive carcinoma); (ii) 44 paired normal and invasive mammary carcinoma patient tissues; (iii) tissue microarray of 1,001 invasive ductal carcinoma patients. ALDH1L1 immunostaining was performed on 1,086 cases (combined samples from the three cohorts) using tissue microarrays or whole section slides with positive cytoplasmic and membranous reactivity. Clinical (tumor size, grade, lymphatic invasion, and lymph node metastasis) data were collected from patient records. Results: ALDH1L1 expression was higher in non-tumor tissues than cancer tissues (p=0.0014 and p=0.0282 for two datasets), and inversely correlated with increased tumor size, advanced stage, and lymphatic spread. Higher ALDH1L1 expression is associated with smaller tumor size, lower pT stage in luminal A and HER2+ subtypes, and lower nuclear grade in triple-negative breast cancer. ALDH1L1 expression was associated with improved overall and disease-free survival, particularly in hormone receptor-positive subtypes (p=0.0049 and p=0.0441). These findings were confirmed by METABRIC database analysis. In agreement with the association between ALDH1L1 expression and tumor aggressiveness, proliferation/clonogenic assays showed strong cytotoxic effects of lentivirus-delivered ALDH1L1 in MCF7 and T47D luminal breast cancer cells. Conclusion: Reduced ALDH1L1 expression is associated with aggressive clinicopathologic features and poorer survival in breast cancer, with a particularly evident and clinically relevant prognostic impact in the luminal A subtype. These findings highlight ALDH1L1 as a subtype-specific favorable biomarker and a potential therapeutic target in hormone receptor-positive breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.